Immunic Therapeutics Presents Advanced MS Treatment Data at Global Conference

Proactive - Interviews for investors

Immunic Therapeutics CEO Dr Daniel Vitt joined Steve Darling from Proactive to discuss the company’s participation at the European Committee for Treatment and Research on Multiple Sclerosis conference, ECTRIMS, the world’s largest event dedicated to multiple sclerosis (MS) research. Dr. Vitt emphasized the significance of this event, where Immunic presented four research posters, including key data on vidofludimus calcium, the company’s leading compound for MS treatment. "We have an advanced asset in multiple sclerosis in development," Dr. Vitt shared, underscoring the critical unmet medical needs in the field. He elaborated on important topics such as progression independent of relapse activity, which remains a challenging aspect of MS treatment. Immunic’s innovative research focuses on the neuroprotective, inflammatory and anti-viral properties of vidofludimus calcium, which could offer new hope to patients with progressive and relapsing forms of the disease. In addition to showcasing their research, Dr. Vitt highlighted the networking opportunities provided by the conference, allowing Immunic to connect with key industry professionals and collaborators in the MS research community. These interactions are essential to advancing both the company’s clinical efforts and its understanding of emerging trends in the field. #proactiveinvestors #immunictherapeutics #DanielVitt #MultipleSclerosis #MSResearch #nasdaq #imux #VidofludimusCalcium #Nurr1Activator #ProgressiveMS #RelapsingMS #Pharma #Biotech #MSDrugDevelopment. #MSResearch #Neuroprotection #ECTRIMS2024 #VidofludimusCalcium #Nurr1 #Neuroinflammation #Biotech #Pharmaceuticals #ClinicalResearch #PIRA #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews